Theriva Biologics To Present Preclinical Data For Potential Synergy Of VCN-01 And First-Line Pancreatic Cancer Chemotherapy Regimens At American Society For Cell And Gene Therapy 27th Annual Meeting
Theriva Biologics To Present Preclinical Data For Potential Synergy Of VCN-01 And First-Line Pancreatic Cancer Chemotherapy Regimens At American Society For Cell And Gene Therapy 27th Annual Meeting
Theriva Biologics 将在美国细胞与基因疗法学会第 27 届年会上提供临床前数据，探讨 VCN-01 和一线胰腺癌化疗方案的潜在协同作用
– Lead product candidate, VCN-01 in combination with liposomal irinotecan demonstrated enhanced anti-tumor effects in a human pancreatic mouse xenograft–
— 主要候选产品，VCN-01 与脂质体伊立替康联合在人胰腺小鼠异种移植中显示出增强的抗肿瘤作用—
– The observed synergy emphasizes VCN-01's potential in diverse chemotherapy combinations for improved efficacy in the treatment of pancreatic cancer–
— 观察到的协同作用凸显了 VCN-01 在多种化疗组合中提高胰腺癌治疗疗效的潜力—